Thursday, 20 October 2016

FDA Approval of 1st Progressive MS Treatment Awaited by Neurologists, Survey Finds

Source Multiple Sclerosis News Today:

Neurologists in the U.S. expect — or, at least, highly anticipate — that Ocrevus (ocrelizumab), being developed by Roche as a treatment for both relapsing and progressive multiple sclerosis (MS), will be approved by year’s end, and a sizable number plan on quickly prescribing it, according to a recent update by Spherix Global Insights in “RealTime Dynamix: Multiple Sclerosis,” a quarterly report based on responses from over 100 neurologists actively treating MS patients.  Read on.